User login
Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US oncology survey
Article Type
Changed
Thu, 12/15/2022 - 18:04
Display Headline
Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US oncology survey
Background Different dosages-schedules of nab-paclitaxel have been assessed in trials of metastatic breast cancer (MBC). However, there is limited information on nab-paclitaxel dosing-scheduling in the community setting.
Objective To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)–negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting.
Methods From September 6-October 21, 2013, a 35-question, web-based survey on nab-paclitaxel dosing, toxicities leading to dose modifications, management, and treatment duration was sent to US Oncology network oncologists. Respondents were categorized by percentage of their patients with HER2-negative MBC who received nab-paclitaxel.
Results 104 of 428 oncologists responded; 84% were from large practices (≥16 oncologists), and 56% had a high level of experience using nab-paclitaxel. For first- and second-line treatment, 100 mg/m2 weekly was the most common starting dosage-schedule, followed by 125 mg/m2 weekly and 260 mg/m2 every 3 weeks (q3w); 150 mg/m2 weekly was used least frequently. Several factors, including select aggressive disease characteristics, were found to affect nab-paclitaxel dose selection. Weekly dosing was preferred in patients with select aggressive disease characteristics, whereas q3w dosing was commonly used in patients aged ≤50 years and those with good performance status. Differences in management styles among oncologists with high compared with infrequent nab-paclitaxel experience were also observed. Peripheral neuropathy and neutropenia were common dose-limiting toxicities.
Limitations Recall and response bias may be limitations of this study.
Conclusions In the community setting, nab-paclitaxel 100 mg/m2 weekly was the most commonly used starting dose for patients with HER2-negative MBC, including those with aggressive disease characteristics.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(5)
Topics
Page Number
173-180
Legacy Keywords
metastatic breast cancer, MBC, nab-paclitaxel, human epidermal growth factor receptor 2-negative, HER2–negative
Sections
Article PDF
Article PDF
Background Different dosages-schedules of nab-paclitaxel have been assessed in trials of metastatic breast cancer (MBC). However, there is limited information on nab-paclitaxel dosing-scheduling in the community setting.
Objective To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)–negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting.
Methods From September 6-October 21, 2013, a 35-question, web-based survey on nab-paclitaxel dosing, toxicities leading to dose modifications, management, and treatment duration was sent to US Oncology network oncologists. Respondents were categorized by percentage of their patients with HER2-negative MBC who received nab-paclitaxel.
Results 104 of 428 oncologists responded; 84% were from large practices (≥16 oncologists), and 56% had a high level of experience using nab-paclitaxel. For first- and second-line treatment, 100 mg/m2 weekly was the most common starting dosage-schedule, followed by 125 mg/m2 weekly and 260 mg/m2 every 3 weeks (q3w); 150 mg/m2 weekly was used least frequently. Several factors, including select aggressive disease characteristics, were found to affect nab-paclitaxel dose selection. Weekly dosing was preferred in patients with select aggressive disease characteristics, whereas q3w dosing was commonly used in patients aged ≤50 years and those with good performance status. Differences in management styles among oncologists with high compared with infrequent nab-paclitaxel experience were also observed. Peripheral neuropathy and neutropenia were common dose-limiting toxicities.
Limitations Recall and response bias may be limitations of this study.
Conclusions In the community setting, nab-paclitaxel 100 mg/m2 weekly was the most commonly used starting dose for patients with HER2-negative MBC, including those with aggressive disease characteristics.
Click on the PDF icon at the top of this introduction to read the full article.
Background Different dosages-schedules of nab-paclitaxel have been assessed in trials of metastatic breast cancer (MBC). However, there is limited information on nab-paclitaxel dosing-scheduling in the community setting.
Objective To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)–negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting.
Methods From September 6-October 21, 2013, a 35-question, web-based survey on nab-paclitaxel dosing, toxicities leading to dose modifications, management, and treatment duration was sent to US Oncology network oncologists. Respondents were categorized by percentage of their patients with HER2-negative MBC who received nab-paclitaxel.
Results 104 of 428 oncologists responded; 84% were from large practices (≥16 oncologists), and 56% had a high level of experience using nab-paclitaxel. For first- and second-line treatment, 100 mg/m2 weekly was the most common starting dosage-schedule, followed by 125 mg/m2 weekly and 260 mg/m2 every 3 weeks (q3w); 150 mg/m2 weekly was used least frequently. Several factors, including select aggressive disease characteristics, were found to affect nab-paclitaxel dose selection. Weekly dosing was preferred in patients with select aggressive disease characteristics, whereas q3w dosing was commonly used in patients aged ≤50 years and those with good performance status. Differences in management styles among oncologists with high compared with infrequent nab-paclitaxel experience were also observed. Peripheral neuropathy and neutropenia were common dose-limiting toxicities.
Limitations Recall and response bias may be limitations of this study.
Conclusions In the community setting, nab-paclitaxel 100 mg/m2 weekly was the most commonly used starting dose for patients with HER2-negative MBC, including those with aggressive disease characteristics.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(5)
Issue
The Journal of Community and Supportive Oncology - 13(5)
Page Number
173-180
Page Number
173-180
Topics
Article Type
Display Headline
Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US oncology survey
Display Headline
Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US oncology survey
Legacy Keywords
metastatic breast cancer, MBC, nab-paclitaxel, human epidermal growth factor receptor 2-negative, HER2–negative
Legacy Keywords
metastatic breast cancer, MBC, nab-paclitaxel, human epidermal growth factor receptor 2-negative, HER2–negative
Sections
Citation Override
JCSO 2015;13:173-180
Disallow All Ads
Alternative CME
Article PDF Media
Document